LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

Home・Lista de Ações・Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals Inc

Fechado

SetorSaúde

37.49 1.65

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

36.04

Máximo

Indicadores-chave
By Trading Economics
Rendimento	7.3M -123M
Vendas	3.7M 3.9M
EPS	-1.29
Margem de lucro	-3,161.261
Funcionários	594
EBITDA	20M -122M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+132.32% upside

Dividendos
By Dow Jones
Próximos Ganhos	6 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-140M 4.3B
Abertura anterior	35.84
Fecho anterior	37.49

Sentimento de Notícias

By Acuity

58%

42%

280 / 346 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

30.39 / 33.46 Suporte e Resistência

Crinetics Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

12 de mai. de 2026, 22:50 UTC

Ganhos

Commonwealth Bank of Australia Increases Provisions as 3Q Profit Slips

12 de mai. de 2026, 22:49 UTC

Ganhos

Aristocrat Leisure Raises Midyear Dividend, Swells Share Buyback Program

12 de mai. de 2026, 22:32 UTC

Ganhos

JBS 1Q Profit Slides Amid Rising Cattle Costs -- Update

12 de mai. de 2026, 23:48 UTC

Conversa de Mercado

Nikkei May Decline Amid Uncertainty Over Iran Conflict -- Market Talk

12 de mai. de 2026, 22:57 UTC

Conversa de Mercado

Ganhos

JBS Says Consumers Are Looking to Pork for Affordable Protein -- Market Talk

12 de mai. de 2026, 22:26 UTC

Ganhos

Aristocrat Leisure to Increase On-Market Share Buyback by A$1 Billion

12 de mai. de 2026, 22:25 UTC

Ganhos

Aristocrat Leisure 1H Normalized Pretax Profit A$997.3 Million, Up 9.4% on Year

12 de mai. de 2026, 22:25 UTC

Ganhos

Aristocrat Leisure Interim Dividend A$0.50/Security

12 de mai. de 2026, 22:24 UTC

Ganhos

Aristocrat Leisure 1H Revenue From Continuing Operations A$3.03 Billion, Down 0.2% on Year

12 de mai. de 2026, 22:23 UTC

Ganhos

Aristocrat Leisure 1H Net Profit From Discontinued Operations A$7.0 Million

12 de mai. de 2026, 22:23 UTC

Ganhos

Aristocrat Leisure 1H Net Profit From Continuing Operations A$798.5 Million, Up 56%

12 de mai. de 2026, 22:19 UTC

Ganhos

CBA: Total Provision Coverage Ratio 1.57%>CBA.AU

12 de mai. de 2026, 22:14 UTC

Ganhos

CBA: Business Lending Continued to Grow Above System>CBA.AU

12 de mai. de 2026, 22:14 UTC

Ganhos

CBA Had 1.4M Business Transaction Accounts at March 31, Up 7% on Year>CBA.AU

12 de mai. de 2026, 22:13 UTC

Ganhos

CBA Household Deposits Grew A$38B in 12 Months Through March>CBA.AU

12 de mai. de 2026, 22:12 UTC

Ganhos

CBA Home Loan Balances Grew A$41B in 12 Months Through March>CBA.AU

12 de mai. de 2026, 22:12 UTC

Ganhos

CBA 3Q New Home Loan Funding A$45B>CBA.AU

12 de mai. de 2026, 22:11 UTC

Ganhos

Correct: JBS NV 1Q EPS 20c, Not 21c >JBS

12 de mai. de 2026, 22:11 UTC

Ganhos

CBA: CET1 Level 2 Capital Ratio 11.6%>CBA.AU

12 de mai. de 2026, 22:10 UTC

Ganhos

CBA: Customer Deposit Funding Ratio 79%>CBA.AU

12 de mai. de 2026, 22:09 UTC

Ganhos

CBA: Underlying Portfolio Credit Quality Remains Sound>CBA.AU

12 de mai. de 2026, 22:09 UTC

Ganhos

CBA: Higher Collective Provisions Reflect Geopolitical, Macroeconomic Uncertainty >CBA.AU

12 de mai. de 2026, 22:08 UTC

Ganhos

CBA 3Q Loan Impairment Expense A$316M>CBA.AU

12 de mai. de 2026, 22:07 UTC

Ganhos

CBA: Costs Up on Higher Cloud Computing Volumes, Software Licenses, AI Investment>CBA.AU

12 de mai. de 2026, 22:06 UTC

Ganhos

CBA 3Q Operating Expenses Up 1% Excluding Restructuring, Notable Items>CBA.AU

12 de mai. de 2026, 22:06 UTC

Ganhos

CBA: 3Q Underlying Net Interest Margin Was Broadly Stable>CBA.AU

12 de mai. de 2026, 22:05 UTC

Ganhos

CBA: Lending, Deposit Volume Growth Offset Impact of Two Fewer Days >CBA.AU

12 de mai. de 2026, 22:04 UTC

Ganhos

Commonwealth Bank: Operating Income Flat in March Quarter >CBA.AU

12 de mai. de 2026, 22:04 UTC

Ganhos

Commonwealth Bank 3Q Cash Profit Up 4% on Year>CBA.AU

12 de mai. de 2026, 22:04 UTC

Ganhos

Commonwealth Bank 3Q Cash Profit Down 1% on 1H Quarterly Average>CBA.AU

Comparação entre Pares

Variação de preço

Crinetics Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

132.32% parte superior

Previsão para 12 meses

Média 85.75 USD 132.32%

Máximo 97 USD

Mínimo 67 USD

Com base em 9 analistas de Wall Street que oferecem metas de preço de 12 meses para Crinetics Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

9 ratings

Comprar

Manter

Vender

Com base em 9 analistas que deram avaliações de ações para Crinetics Pharmaceuticals Inc - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

30.39 / 33.46Suporte e Resistência

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentimento

By Acuity

280 / 346 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.